Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron
Shots:
- The P-III (ACHIEVE-1) trial assessed orforglipron vs PBO in T2D adults (n=559) having inadequate glycemic control with diet & exercise alone; subjects started at 1mg QD, with dose escalation at every Q4W till assigned doses of 3, 12mg (via 1, 3 & 6mg), or 36mg (via 1, 3, 6, 12, & 24mg)
- Trial met its 1EP at 40wks., with orforglipron (3, 12, 36mg) showing superior A1C reduction (baseline: 8%) by 1.3%, 1.6%, & 1.5% vs 0.1%. In 2EP, >65% pts. on 36mg achieved ≤6.5% A1C & weight loss of 4.4kg, 5.5kg & 7.3kg vs 1.3kg from the baseline of 90.2kg; weight plateau was not reached by study end
- The overall safety and tolerability was consistent throughout the trial; Lilly plans to submit for weight management approval by H2'25 and T2D in 2026
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
